Hillstream BioPharma EBIT

The latest EBIT for HILS is $-54M as of March 2026. That compares with $-14M in the prior-year period — down 284.3% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Hillstream BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, HILS's EBIT moved from $-14M to $-54M — a 284.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hillstream BioPharma's operating scale or balance-sheet position.

Against its sector companies, HILS currently prints $-54M for EBIT, while the sector average sits near $-63M. That is roughly 13.0% above the sector mean. Large gaps often invite a closer look at Hillstream BioPharma's growth, margins, and balance sheet.

A EBIT figure of $-54M for HILS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting HILS's EBIT ($-54M), review year-over-year change from $-14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.